Compare Heron Therapeutics Inc (HRTX) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Suncor Energy Inc. — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Suncor Energy Inc. trades at $72.18 (market cap $82.76B). The key difference: Suncor Energy Inc. is far larger — about 1216.9× Heron Therapeutics Inc's market cap, and Suncor Energy Inc. pays a 2.39% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Suncor Energy Inc. for 57 Days on average.
| HRTX | SU | |
|---|---|---|
Market Cap | $68.01M | $82.76B |
Volume | 1,891,941 | 3,832,959 |
Sector | Health | Energy |
52-Week High | $1.49 | $71.87 |
52-Week Low | $0.27 | $38.17 |
Typical Hold Time | 35 Days | 57 Days |
Enterprise Value | $174.75M | $89.29B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Suncor Energy (SU) trades at $72.23, up 6.0% today and near its 52-week high, reflecting strong momentum. The stock shows bullish technical signals with moving averages supporting further upside, while fundamentals indicate solid profitability with a 14.7% net income margin and attractive valuation at a P/E of 13.46. Recent Q2 2026 earnings beat expectations, and the company is boosting shareholder returns through buybacks and a $0.60 dividend.
The outlook remains positive given robust cash flow, debt reduction, and strategic asset sales, but risks include commodity price volatility and operational disruptions. With 74% analyst buy ratings and institutional confidence, SU offers value in the energy sector, though investors should monitor execution under new leadership and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
